News - Santhera Pharmaceuticals

Filter

Current filters:

Santhera Pharmaceuticals

Popular Filters

EMA validates Santhera’s Marketing Authorization Application for Raxone

EMA validates Santhera’s Marketing Authorization Application for Raxone

05-06-2014

The European Medicines Agency has validated a Marketing Authorization Application (MAA) for Leber’s…

EuropeOphthalmicsPharmaceuticalRaxoneRegulationSanthera Pharmaceuticals

Santhera muscular dystrophy drug shows success first time in late clinical trial

22-05-2014

For the first time, a drug for Duchenne muscular dystrophy (DMD) – from Swiss drugmaker Santhera Pharmaceuticals…

CatenaPharmaceuticalRare diseasesRaxoneResearchSanthera Pharmaceuticals

Positive Ph III results with Santhera’s Catena/Raxone in Duchenne muscular dystrophy

14-05-2014

Swiss drugmaker Santhera Pharmaceuticals has released positive Phase III, double-blind, placebo-controlled…

CatenaPharmaceuticalRare diseasesRaxoneResearchSanthera Pharmaceuticals

Santhera re-files for EU approval of Raxone in the treatment of LHON

07-05-2014

Swiss drugmaker Santhera Pharmaceuticals has re-filed its Marketing Authorization Application for Raxone…

EuropeOphthalmicsPharmaceuticalRare diseasesRaxoneSanthera Pharmaceuticals

Santhera presents new efficacy data with Raxone for Leber's hereditary optic neuropathy

04-03-2014

Swiss specialty drugmaker Santhera Pharmaceuticals says that current data from the expanded access program…

OphthalmicsPharmaceuticalRaxoneResearchSanthera Pharmaceuticals

Santhera's Raxone granted temporary use in France

21-01-2014

Switzerland-based Santhera Pharmaceuticals (SIX: SANN) announced today that the French National Agency…

FranceNeurologicalPharmaceuticalRaxoneRegulationSanthera Pharmaceuticals

Santhera regains Catena European rights

04-09-2013

Switzerland-based Santhera Pharmaceuticals (SIX: SANN) says that it has reached an agreement with Takeda…

CatenaEuropeLicensingPharmaceuticalRare diseasesSanthera PharmaceuticalsTakeda Pharmaceuticals

Santhera gets exclusive rights from NIH for novel approach to pp multiple sclerosis treatment

06-06-2013

Swiss Santhera Pharmaceuticals (SIX: SANN) says that it has obtained an exclusive license from the USA's…

CatenaLicensingNeurologicalPatentsPharmaceuticalSanthera Pharmaceuticals

IDSMB backs continuation of Santhera's Ph III Catena trial in DMD, but now needs partner

16-04-2013

Swiss drugmaker Santhera Pharmaceuticals (SIX: SANN) says that the Phase III DELOS study of orally administered…

CatenaLicensingPharmaceuticalRare diseasesResearchSanthera Pharmaceuticals

Good EMA news for Pfizer's Bosulif but not for Santhera's Raxone

21-01-2013

Following its monthly meetings last week, the European Medicines Agency the Committee for Medicinal Products…

BiotechnologyBosulifEuropeOncologyOphthalmicsPfizerPharmaceuticalRaxoneRegulationSanthera Pharmaceuticals

Ipsen returns rights to Parkinson’s drug to Santhera

26-01-2012

Switzerland’s Santhera Pharmaceuticals (SIX:SANN) and French drugmaker Ipsen (Euronext: IPN) have…

fipamezoleIpsenLicensingNeurologicalPharmaceuticalSanthera Pharmaceuticals

Back to top